DK1353688T3 - Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet - Google Patents

Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet

Info

Publication number
DK1353688T3
DK1353688T3 DK02706015T DK02706015T DK1353688T3 DK 1353688 T3 DK1353688 T3 DK 1353688T3 DK 02706015 T DK02706015 T DK 02706015T DK 02706015 T DK02706015 T DK 02706015T DK 1353688 T3 DK1353688 T3 DK 1353688T3
Authority
DK
Denmark
Prior art keywords
antigen
psedomonas
immunization
compositions
methods
Prior art date
Application number
DK02706015T
Other languages
English (en)
Inventor
Dara W Frank
Jeannine Wiener-Kronish
Timothy L Yahr
Teiji Sawa
Robert B Fritz
Original Assignee
Mcw Res Found Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/770,916 external-priority patent/US6827935B2/en
Application filed by Mcw Res Found Inc, Univ California filed Critical Mcw Res Found Inc
Application granted granted Critical
Publication of DK1353688T3 publication Critical patent/DK1353688T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
DK02706015T 2001-01-26 2002-01-25 Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet DK1353688T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/770,916 US6827935B2 (en) 1998-11-25 2001-01-26 Method of and compositions for immunization with the pseudomonas V antigen
US26479501P 2001-01-29 2001-01-29
PCT/US2002/002382 WO2002064161A2 (en) 2001-01-26 2002-01-25 Method and compositions for immunization with the pseudomonas v antigen

Publications (1)

Publication Number Publication Date
DK1353688T3 true DK1353688T3 (da) 2007-04-10

Family

ID=26950766

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02706015T DK1353688T3 (da) 2001-01-26 2002-01-25 Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet

Country Status (8)

Country Link
US (2) US7494653B2 (da)
EP (1) EP1353688B1 (da)
JP (1) JP4355786B2 (da)
AT (1) ATE347374T1 (da)
DE (1) DE60216564T2 (da)
DK (1) DK1353688T3 (da)
ES (1) ES2275840T3 (da)
WO (1) WO2002064161A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7075502B1 (en) 1998-04-10 2006-07-11 E Ink Corporation Full color reflective display with multichromatic sub-pixels
EP1790659B1 (en) * 2001-11-13 2013-07-31 ID Biomedical Corporation Polypeptides of pseudomonas aeruginosa
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
AU2003248233A1 (en) 2003-08-01 2005-02-15 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences A method of preparing epitopes chimeric gene vaccine
US20090208535A1 (en) * 2004-06-28 2009-08-20 Proteome Systems Intellectual Property Pty Ltd Novel Methods of Diagnosis of Treatment of P. Aeruginosa Infection and Reagents Therefor
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
AU2009203426C1 (en) 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
WO2010091189A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
DK2407537T6 (da) * 2009-03-11 2015-07-27 Shionogi & Co Humaniseret pcrv-antistof med antipseudomonal aktivitet
CN104597651B (zh) 2009-05-02 2017-12-05 株式会社半导体能源研究所 显示设备
KR101711678B1 (ko) 2009-05-02 2017-03-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 전자 장치
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
MX2014010495A (es) * 2012-03-02 2014-11-14 Ablynx Nv Polipeptidos que enlazan a pcrv.
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
US12077827B2 (en) 2017-09-29 2024-09-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the risk of developing pulmonary colonization/infection by Pseudomonas aeruginosa
BR112021023335A2 (pt) 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
EP3997121A4 (en) 2019-07-09 2024-03-27 Beijing SoloBio Genetechnology Company Ltd. ANTIBODIES THAT SPECIFICALLY RECOGNIZE PSEUDOMONAS PCRV AND THEIR USES
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
EP4735478A1 (en) 2023-06-28 2026-05-06 Universität zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599665A (en) 1993-12-21 1997-02-04 Mcw Research Foundation Pseudomonas aeruginosa nucleic acids encoding exoenzyme S activity and use thereof in detecting pseudomonas aeruginosa infection
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
CA2318536C (en) * 1998-11-25 2009-11-17 Mcw Research Foundation, Inc. Method of and compositions for immunization with the pseudomonas v antigen

Also Published As

Publication number Publication date
JP2005500250A (ja) 2005-01-06
ATE347374T1 (de) 2006-12-15
WO2002064161A3 (en) 2002-12-12
US20050063985A1 (en) 2005-03-24
JP4355786B2 (ja) 2009-11-04
US20090191241A1 (en) 2009-07-30
EP1353688A2 (en) 2003-10-22
WO2002064161A9 (en) 2002-10-31
EP1353688B1 (en) 2006-12-06
DE60216564T2 (de) 2007-10-11
ES2275840T3 (es) 2007-06-16
DE60216564D1 (de) 2007-01-18
WO2002064161A2 (en) 2002-08-22
US7494653B2 (en) 2009-02-24
US8101347B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
DK1049488T3 (da) Fremgangsmåde og præparat til immunisering med Pseudomonas aeruginosa-V-antigenet
ATE347374T1 (de) Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
DE122010000042I1 (de) Solubilisierung von capsulären Polysacchariden
DK1535068T3 (da) Anordninger og fremgangsmåder til detektering af fostervand i vaginalsekreter
DE69533673D1 (de) Behandlung und prävention von helicobacter-infektionen
DE69527986D1 (de) Antigene arznei zur behandlung oder vorbeugung
ATE244578T1 (de) Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
EP1395283A4 (en) HETEROLOGICAL PROTECTION, INDUCED BY IMMUNIZATION WITH THE INVAPLEX VACCINE
UA92721C2 (ru) Обогащенная популяция антител, высокоспецифических к антигену поверхностного полисахарида липоарабиноманана (lam) микобактерии, способ выявления микобактериальной инфекции в образце и набор для выявления микобактериальной инфекции
AP2001002073A0 (en) Neutralizing antibody and immunomodulatory enhancing compositions
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
WO2003006055A3 (en) Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
EP0836480A4 (en) COMPOSITIONS THAT PROVIDE ADP-RIBOSYL TRANSFERASE ACTIVITY AND METHODS FOR THEIR PRODUCTION AND USE
DK0809653T3 (da) Helicobacter pylori-antigen
AU2002324486A1 (en) Mutants of clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith
DK1183044T3 (da) Adjuvanskombinationer til immunisering og vacciner
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
WO2002030321A3 (en) Bird diagnostics and treatments